Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. junior Avg
|
New words:
AAA, abbreviated, Abigail, accessibility, accessing, adenocarcinoma, advisor, aldoxorubicin, alliance, Alora, amifampridine, ANDA, antitrust, APA, Aptevo, arimoclomol, array, Arsenal, assigned, Assignment, assimilate, assumption, authentication, AVEO, Bain, bear, behavioral, bioavailability, bioequivalent, Bioscience, Blaze, bleeding, block, Blue, body, Boston, Box, BPCIA, Brookside, capacity, Carlo, Catalyst, Cayman, certified, Chapel, China, chronic, chronically, coagulation, Columbia, compel, compliant, congenital, Connecticut, Cullinan, Dartmouth, debilitating, defective, disaggregation, divested, division, Doctor, DoD, downgrade, downtime, doxorubicin, drawn, DSUVIA, ductal, East, email, encryption, endorse, endpoint, escalation, escrow, exarafenib, FDCA, FDIC, Fidelity, FMR, Foresite, formulation, FS, fundraising, genetic, glioma, goal, GPH, Grand, Gurnet, Head, Hemophilia, highlight, House, hurdle, hurt, hyperinsulinism, ICAV, Ikena, immaterial, ImmunityBio, implicated, incident, incubated, IND, ineffective, infancy, Intarcia, interchangeable, Irish, IX, IXINITY, Ji, KBSIII, KemPharm, Kinnate, LadRx, lender, lien, literate, longstanding, malware, managerial, mechanism, media, Medicinal, medicine, melanoma, messenger, Middle, moiety, monetization, monotherapy, Monte, MTS, myasthenic, NantCell, NCE, nonclinical, North, notification, occasionally, occlusion, oncology, Orphazyme, outlining, overlapping, Owl, Parent, password, patch, pattern, pediatric, Pennsylvania, perfected, perimeter, peripheral, Phoenix, pool, postoperative, potency, premise, prioritize, promptly, PSU, pure, purity, quantity, radio, ransomware, recapitalization, receivership, recombinant, recourse, redomiciled, regular, relapsed, repurchase, resemble, resubmission, retinal, retrain, revert, RNA, rollover, route, routine, routinely, RTW, safeguard, Sail, Sanofi, scanning, seller, sentiment, shortfall, show, showing, Silvergate, Simplification, slower, Sociology, software, sooner, sought, spent, Square, stop, strength, stronger, sublingual, subsidized, subtitle, sufentanil, Summer, swept, tablet, Taiwan, talent, Talphera, television, tender, tighter, timeframe, tovorafenib, toxic, tracing, traditional, training, tranche, Translate, Ugland, unaccreted, uncured, undertaken, undisclosed, Utah, vehicle, vein, version, vigorously, vii, visibility, web, Wharton, wild, Xing, XRA, XRL, Zevra
Removed:
acute, affinity, attack, Bay, bind, breakdown, CEO, Chapter, commerce, comprising, continual, continuously, conviction, coronary, curtailed, deadline, Denman, diligent, discontinued, eighty, enzyme, expansive, exploit, foundation, Genentech, goodwill, gout, hacker, hereto, hundred, ideal, indemnified, infarction, joint, Lastly, living, Lysosomal, minimal, month, myocardial, outbreak, percent, prevalent, principally, protein, proxy, pursuit, recurrence, reducing, referring, relief, replacing, sector, sequester, Sesen, South, spread, strict, Subtopic, Taxpayer, TGFb, thrombin, tier, warning
Filing tables
Filing exhibits
Related press release
XOMA similar filings
Filing view
External links
Exhibit 23.1
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We consent to the incorporation by reference in Registration Statement Nos. 333-269459, 333-151416, 333-171429, 333-174730, 333-181849, 333-198719, 333-204367, 333-212238, 333-218378, 333-232398, 333-265248 and 333-272054 on Form S-8 and Registration Statement No. 333-254073 on Form S-3 of our report dated March 8, 2024, relating to the consolidated financial statements of XOMA Corporation, appearing in this Annual Report on Form 10-K for the year ended December 31, 2023.
/s/ Deloitte & Touche LLP
San Francisco, California
March 8, 2024